- Home
- SGLY vs SLRX Comparison
SGLY vs SLRX Comparison
Compare SGLY & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- SLRX
- Stock Information
- Founded
- SGLY 2001
- SLRX N/A
- Country
- SGLY United States
- SLRX United States
- Employees
- SGLY N/A
- SLRX N/A
- Industry
- SGLY
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- SLRX Health Care
- Exchange
- SGLY Nasdaq
- SLRX Nasdaq
- Market Cap
- SGLY 3.4M
- SLRX 3.6M
- IPO Year
- SGLY 2008
- SLRX N/A
- Fundamental
- Price
- SGLY $0.69
- SLRX $3.86
- Analyst Decision
- SGLY
- SLRX
- Analyst Count
- SGLY 0
- SLRX 0
- Target Price
- SGLY N/A
- SLRX N/A
- AVG Volume (30 Days)
- SGLY 320.7K
- SLRX 273.4K
- Earning Date
- SGLY 10-14-2025
- SLRX 11-13-2025
- Dividend Yield
- SGLY N/A
- SLRX N/A
- EPS Growth
- SGLY N/A
- SLRX N/A
- EPS
- SGLY N/A
- SLRX N/A
- Revenue
- SGLY $1,813,193.00
- SLRX N/A
- Revenue This Year
- SGLY N/A
- SLRX N/A
- Revenue Next Year
- SGLY N/A
- SLRX N/A
- P/E Ratio
- SGLY N/A
- SLRX N/A
- Revenue Growth
- SGLY N/A
- SLRX N/A
- 52 Week Low
- SGLY $0.54
- SLRX $3.16
- 52 Week High
- SGLY $5.49
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- SGLY 36.09
- SLRX 47.32
- Support Level
- SGLY $0.67
- SLRX $3.67
- Resistance Level
- SGLY $0.85
- SLRX $3.97
- Average True Range (ATR)
- SGLY 0.06
- SLRX 0.34
- MACD
- SGLY 0.00
- SLRX -0.06
- Stochastic Oscillator
- SGLY 18.59
- SLRX 46.66
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.